Sulifei Ferrous Succinate Sustained Release Tablets

1. Indications and Usage
Iron Deficiency Anemia: Indicated for the treatment of iron deficiency anemia caused by chronic blood loss, poor nutrition, or malabsorption.
Prevention: Used to prevent iron deficiency in patients with increased requirements, such as during pregnancy or in cases of chronic debilitation.
2. Dosage and Administration
Standard Dose: The usual dosage for adults is 100–200 mg of elemental iron once daily, taken orally.
Administration: Should be taken on an empty stomach (1 hour before or 2 hours after meals) with water or orange juice to enhance absorption.
Duration: Treatment should continue for at least 3–6 months after hemoglobin levels normalize to replenish iron stores.
3. Mechanism of Action
Heme Synthesis: Iron is an essential component of heme, the oxygen-carrying part of hemoglobin in red blood cells.
Oxygen Transport: By replenishing iron stores, the drug facilitates the synthesis of hemoglobin, thereby improving oxygen transport to tissues and correcting anemia.
4. Safety and Warnings
Gastrointestinal Toxicity: The most common adverse effects include nausea, epigastric pain, constipation, or diarrhea.
Overdose Risk: Iron overdose can be fatal, especially in young children. Keep out of reach of children.
Hemochromatosis: Contraindicated in patients with hemochromatosis, hemosiderosis, or other disorders of iron metabolism.
5. Adverse Reactions and Clinical Research
Common Adverse Reactions: Black stools (harmless), nausea, epigastric discomfort, constipation, and diarrhea.
Serious Adverse Reactions: Severe allergic reactions, gastrointestinal ulceration or bleeding (rare).
Clinical Findings: Clinical evidence supports the efficacy of sustained-release formulations in reducing gastrointestinal irritation while maintaining iron absorption.
6. Drug Interactions
Antacids: Aluminum-containing antacids decrease iron absorption.
Tetracyclines/Quinolones: Iron decreases the absorption of these antibiotics.
Levodopa: Iron may reduce the efficacy of levodopa.
Folic Acid: Concurrent use may enhance the hematologic response.
7. Pharmaceutical Information
Active Ingredient: Ferrous Succinate.
Strengths: Typically available as 100 mg or 200 mg sustained-release tablets.
Appearance: Various colors depending on the coating, often film-coated to control release.
Storage: Store in a tight, light-resistant container, protected from moisture and heat.